Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis

AIMS/HYPOTHESIS: Sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely used in the treatment of type 2 diabetes, heart failure and chronic kidney disease. Their role in the prevention of diet-induced metabolic deteriorations, such as obesity, insulin resistance and fatty liver disease, has no...

Descripción completa

Detalles Bibliográficos
Autores principales: Radlinger, Bernhard, Ress, Claudia, Folie, Sabrina, Salzmann, Karin, Lechuga, Ana, Weiss, Bernhard, Salvenmoser, Willi, Graber, Michael, Hirsch, Jakob, Holfeld, Johannes, Kremser, Christian, Moser, Patrizia, Staudacher, Gabriele, Jelenik, Tomas, Roden, Michael, Tilg, Herbert, Kaser, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947060/
https://www.ncbi.nlm.nih.gov/pubmed/36525084
http://dx.doi.org/10.1007/s00125-022-05851-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947060/
https://www.ncbi.nlm.nih.gov/pubmed/36525084
http://dx.doi.org/10.1007/s00125-022-05851-x

Ejemplares similares